(Circulation. 1995;92:962-967.)
© 1995 American Heart Association, Inc.
Articles |
Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots
From the Cardiovascular Division, Washington University School of Medicine, St Louis, Mo.
Correspondence to Paul R. Eisenberg, MD, MPH, Cardiovascular Division, Box 8086, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110.
Background Thrombi are known to induce activation of the coagulation system, which may be a mechanism for progression of thrombosis and its recurrence after thrombolysis. This study was designed to characterize the relative role of thrombin and activated factor X (factor Xa) as mediators of procoagulant activity of whole blood clots in blood and plasma.
Methods and Results Clots formed from human blood were incubated in recalcified (25 mmol/L CaCl2) citrated plasma or nonanticoagulated blood with increasing concentrations of recombinant desulfatohirudin (hirudin) to inhibit thrombin activity, recombinant tick anticoagulant peptide (TAP) or recombinant tissue factor pathway inhibitor (TFPI) to inhibit factor Xa, or heparin. Fibrinopeptide A (FPA) was assayed serially as an index of procoagulant (thrombin) activity. FPA generation was greatly accelerated by addition of clots to recalcified plasma (from 1251±211 ng/mL after 15 minutes without clot to 5916±1412 ng/mL with clot, n=7, P<.01) or whole blood (4803±761 ng/mL with clot compared with 546±233 without clot, n=5, P<.05) and was attenuated by inhibitors of thrombin (>90% inhibition of FPA with 0.05 µmol/L hirudin and 1.0 U/mL heparin) and factor Xa (>90% inhibition of FPA with 1.0 µmol/L TAP and 0.15 µmol/L TFPI) in a concentration-dependent manner. Preincubation of clots with tissue-type plasminogen activator sufficient to induce partial clot lysis increased the rate of thrombin-induced FPA generation by increasing the surface area of clot exposed to plasma. However, procoagulant activity induced by partially lysed clots was attenuated by lower concentrations of both thrombin and Xa inhibitors, presumably because access of the inhibitors to bound procoagulant molecules was facilitated. Comparable results were obtained with incubations in nonanticoagulated blood.
Conclusions These results indicate that factor Xa is primarily responsible for the procoagulant activity of clots in vitro and suggest a potential molecular mechanism for the observed efficacy of inhibitors of factor Xa in preventing recurrent thrombosis after coronary thrombolysis.
Key Words: thrombosis • thrombolysis • plasminogen activators • anticoagulants
This article has been cited by other articles:
 |
|
 |
|
  K. Borensztajn, J. Stiekema, S. Nijmeijer, P. H. Reitsma, M. P. Peppelenbosch, and C. A. Spek Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation Am. J. Pathol., February 1, 2008; 172(2): 309 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Pospisil, A. R. Stafford, J. C. Fredenburgh, and J. I. Weitz Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin J. Biol. Chem., June 6, 2003; 278(24): 21584 - 21591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Hyers Management of Venous Thromboembolism: Past, Present, and Future Arch Intern Med, April 14, 2003; 163(7): 759 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K.C. Chan, J. Rak, L. Berry, P. Liao, M. Vlasin, J. Weitz, and P. Klement Antithrombin-Heparin Covalent Complex: A Possible Alternative to Heparin for Arterial Thrombosis Prevention Circulation, July 9, 2002; 106(2): 261 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Abendschein, P. K. Baum, P. Verhallen, P. R. Eisenberg, M. E. Sullivan, and D. R. Light A Novel Synthetic Inhibitor of Factor Xa Decreases Early Reocclusion and Improves 24-h Patency after Coronary Fibrinolysis in Dogs J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 567 - 572. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. C. Becker, F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1020 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, B. Leslie, and M. Hudoba Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors Circulation, February 17, 1998; 97(6): 544 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ghigliotti, A. R. Waissbluth, C. Speidel, D. R. Abendschein, and P. R. Eisenberg Prolonged Activation of Prothrombin on the Vascular Wall After Arterial Injury Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 250 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Hérault, A. Bernat, A. M. Pflieger, J. C. Lormeau, and J. M. Herbert Comparative Effects of Two Direct and Indirect Factor Xa Inhibitors on Free and Clot-Bound Prothrombinase J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 16 - 22. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Kaiser State-of-the-Art Review: Factor Xa Versus Factor IIa Inhibitors Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 16 - 24. [Abstract] [PDF]
|
|
|
|
|
|
C. R. McKenzie, D. R. Abendschein, and P. R. Eisenberg Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa Arterioscler Thromb Vasc Biol, October 1, 1996; 16(10): 1285 - 1291. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.M. Herbert, J.P. Herault, A. Bernat, R.G.M. van Amsterdam, G.M.T. Vogel, J.C. Lormeau, M. Petitou, and D.G. Meuleman Biochemical and Pharmacological Properties of SANORG 32701: Comparison With the `Synthetic Pentasaccharide' (SR 90107/ORG 31540) and Standard Heparin Circ. Res., September 1, 1996; 79(3): 590 - 600. [Abstract] [Full Text]
|
|